Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine

被引:10
作者
Pridal, L [1 ]
Agerbaek, H [1 ]
Christensen, LN [1 ]
Thomsen, K [1 ]
Kirk, O [1 ]
机构
[1] NOVO NORDISK AS,PHARMACEUT DEV,DK-2880 BAGSVAERD,DENMARK
关键词
glucagon-like peptide-1; GLP-1(7-36)amide; sc preparations; zinc; protamine; pharmacokinetics;
D O I
10.1016/0378-5173(95)04480-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics of several different preparations for subcutaneous administration of GLP-1(7-36)amide (GLP-1) were studied. The difference between soluble GLP-1 at pH 4.0 and a suspension of GLP-1 crystals at pH 6.9, and how addition of zinc chloride or protamine sulphate to the GLP-1 suspension affected the absorption kinetics after s.c. administration, were investigated. Four Beagle dogs received 50 mu g/kg of GLP-1 s.c. in different vehicle compositions. The vehicle contained 1 mg/ml of GLP-1, 10 mmol/l disodium phosphate, 16 mg/ml glycerol, and in some preparations either zinc chloride or protamine sulphate. The preparations were: (1) pH 4.0, (2) pH 6.9, (3) 1 equiv. (relative to GLP-1) zinc chloride pH 6.9, (4) 0.5 equiv. zinc chloride pH 6.9, (5) 3 equiv. zinc chloride pH 6.9, (6) 0.5 mg/ml protamine sulphate pH 4.0, and (7) 0.5 mg/ml protamine sulphate pH 6.9. Plasma samples were analyzed employing a sandwich enzyme-linked immunosorbant assay. Addition of zinc chloride or protamine sulphate to the GLP-1 suspension decreased the absorption rate. The plasma concentration of GLP-1 was increased to a pharmacological level for at least 15 h when administered s.c. as a zinc or protamine suspension. Furthermore, the peak plasma concentration was flattened out, when the peptide was administered as a suspension containing zinc chloride or protamine sulphate, compared to a solution.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 15 条
[1]  
ADELHORST K, 1994, J BIOL CHEM, V269, P6275
[2]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[3]   GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SECRETION IN RESPONSE TO NUTRIENT INGESTION IN MAN - ACUTE POSTPRANDIAL AND 24-H SECRETION PATTERNS [J].
ELLIOTT, RM ;
MORGAN, LM ;
TREDGER, JA ;
DEACON, S ;
WRIGHT, J ;
MARKS, V .
JOURNAL OF ENDOCRINOLOGY, 1993, 138 (01) :159-166
[4]   IMPROVING INSULIN THERAPY - ACHIEVEMENTS AND CHALLENGES [J].
GALLOWAY, JA ;
CHANCE, RE .
HORMONE AND METABOLIC RESEARCH, 1994, 26 (12) :591-598
[5]   ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS [J].
GUTNIAK, M ;
ORSKOV, C ;
HOLST, JJ ;
AHREN, B ;
EFENDIC, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1316-1322
[6]   SUBCUTANEOUS INJECTION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 ABOLISHES POSTPRANDIAL GLYCEMIA IN NIDDM [J].
GUTNIAK, MK ;
LINDE, B ;
HOLST, JJ ;
EFENDIC, S .
DIABETES CARE, 1994, 17 (09) :1039-1044
[7]  
Heinzel G., 1993, PHARMACOKINETIC PHAR
[8]   NORMALIZATION OF FASTING HYPERGLYCEMIA BY EXOGENOUS GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS [J].
NAUCK, MA ;
KLEINE, N ;
ORSKOV, C ;
HOLST, JJ ;
WILLMS, B ;
CREUTZFELDT, W .
DIABETOLOGIA, 1993, 36 (08) :741-744
[9]  
ORSKOV C, 1992, DIABETOLOGIA, V35, P701
[10]  
PINGEL M, 1993, HDB EXPT PHARM, V66, pCH8